Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States
- PMID: 20572763
- DOI: 10.1086/653932
Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States
Abstract
Background: Escherichia coli sequence type ST131 (O25:H4), associated with the CTX-M-15 extended-spectrum beta-lactamase, has emerged internationally as a multidrug-resistant pathogen but has received little attention in the United States.
Methods: From the SENTRY and Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) surveillance programs, 127 E. coli clinical isolates from hospitalized patients across the United States in 2007, stratified by extended-spectrum cephalosporin and fluoroquinolone phenotype and bla(CTX-M-15) genotype, were assessed for phylogenetic group, ST131 status, susceptibility profile, virulence genotype, gyrA and parC sequence, and pulsed-field gel electrophoresis profile.
Results: The 54 identified ST131 isolates (all fluoroquinolone resistant) accounted for an estimated 17% of the source populations, including 67%-69% of isolates resistant to extended-spectrum cephalosporins or fluoroquinolones, 55% of those resistant to both fluoroquinolones and trimethoprim-sulfamethoxazole, and 52% of multidrug-resistant isolates. Their distinctive virulence profiles were more extensive compared with other antimicrobial-resistant isolates but similarly extensive compared with antimicrobial-susceptible isolates. Pulsed-field profiling suggested ongoing dissemination among locales, with concentration of bla(CTX-M-15) within specific ST131 lineages. A historical ST131 isolate lacked the 2007 ST131 isolates' conserved fluoroquinolone resistance-associated single-nucleotide polymorphisms in gyrA and parC.
Conclusions: A single E. coli clonal group, ST131, probably caused the most significantly antimicrobial-resistant E. coli infections in the United States in 2007, thereby constituting an important new public health threat. Enhanced virulence and/or antimicrobial resistance compared with other E. coli, plus ongoing dissemination among locales, may underlie ST131's success. Urgent investigation of the sources and transmission pathways of ST131 is needed to inform mitigation efforts.
Comment on
-
The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients.Clin Infect Dis. 2010 Aug 1;51(3):280-5. doi: 10.1086/653931. Clin Infect Dis. 2010. PMID: 20597679 Free PMC article.
Similar articles
-
Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.Chemotherapy. 2012;58(1):52-9. doi: 10.1159/000336129. Epub 2012 Feb 15. Chemotherapy. 2012. PMID: 22343392
-
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.Antimicrob Agents Chemother. 2012 May;56(5):2364-70. doi: 10.1128/AAC.05824-11. Epub 2012 Feb 21. Antimicrob Agents Chemother. 2012. PMID: 22354301 Free PMC article.
-
Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.Clin Infect Dis. 2013 Nov;57(9):1256-65. doi: 10.1093/cid/cit503. Epub 2013 Aug 6. Clin Infect Dis. 2013. PMID: 23926176 Free PMC article.
-
Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.J Antimicrob Chemother. 2009 Jun;63(6):1135-41. doi: 10.1093/jac/dkp122. Epub 2009 Apr 7. J Antimicrob Chemother. 2009. PMID: 19351692
-
Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.J Infect Dis. 2013 Mar 15;207(6):919-28. doi: 10.1093/infdis/jis933. Epub 2013 Jan 3. J Infect Dis. 2013. PMID: 23288927 Free PMC article.
Cited by 227 articles
-
Wild Boars as an Indicator of Environmental Spread of ESβL-Producing Escherichia coli.Front Microbiol. 2022 Apr 1;13:838383. doi: 10.3389/fmicb.2022.838383. eCollection 2022. Front Microbiol. 2022. PMID: 35432265 Free PMC article.
-
CpxA Phosphatase Inhibitor Activates CpxRA and Is a Potential Treatment for Uropathogenic Escherichia coli in a Murine Model of Infection.Microbiol Spectr. 2022 Apr 27;10(2):e0243021. doi: 10.1128/spectrum.02430-21. Epub 2022 Mar 17. Microbiol Spectr. 2022. PMID: 35297652 Free PMC article.
-
Population snapshot of the extended-spectrum β-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital.Ann Clin Microbiol Antimicrob. 2022 Feb 10;21(1):3. doi: 10.1186/s12941-022-00493-8. Ann Clin Microbiol Antimicrob. 2022. PMID: 35144632 Free PMC article.
-
Isolation of Human Lineage, Fluoroquinolone-Resistant and Extended-β-Lactamase-Producing Escherichia coli Isolates from Companion Animals in Japan.Antibiotics (Basel). 2021 Nov 28;10(12):1463. doi: 10.3390/antibiotics10121463. Antibiotics (Basel). 2021. PMID: 34943675 Free PMC article.
-
Phage Therapy Related Microbial Succession Associated with Successful Clinical Outcome for a Recurrent Urinary Tract Infection.Viruses. 2021 Oct 12;13(10):2049. doi: 10.3390/v13102049. Viruses. 2021. PMID: 34696479 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
